Squarepoint’s Albany Molecular Research Inc AMRI Stock Holding History

Squarepoint’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-12,053	Closed	-$169K	–	2009
2017 Q1	$169K	Buy	+12,053	New	+$197K	﹤0.01%	1326

Other funds holding AMRI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Chicago Capital Management Chicago, Illinois $121M AUM 74.36% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Squarepoint's AMRI Position: Q2 2017 in Review

Squarepoint sold out of Albany Molecular Research Inc (AMRI) in Q2 2017, closing a stake of 12,053 shares — an estimated $169K sold.

Squarepoint first reported a position in AMRI in Q1 2017 and held it in 1 quarter. The position peaked at $169K in Q1 2017. 136 funds tracked by Wall St. Rank hold AMRI as of Q2 2017.

Squarepoint reported no remaining Albany Molecular Research Inc position as of Q2 2017 after selling out during the quarter.
Squarepoint sold 12,053 Albany Molecular Research Inc shares in Q2 2017, an estimated $169K.
Squarepoint first reported a position in Albany Molecular Research Inc in Q1 2017 and held it in 1 quarter.
Squarepoint's Albany Molecular Research Inc position peaked at $169K in Q1 2017.
136 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q2 2017.

Based on Squarepoint's 13F filing for Q2 2017, filed 14 Aug 2017.